Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma
Nakaoka, T.; Saito, Y.; Saito, H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. Int. J. Mol. Sci. 2017, 18, 1111. https://doi.org/10.3390/ijms18061111
Nakaoka T, Saito Y, Saito H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. International Journal of Molecular Sciences. 2017; 18(6):1111. https://doi.org/10.3390/ijms18061111
Chicago/Turabian StyleNakaoka, Toshiaki, Yoshimasa Saito, and Hidetsugu Saito. 2017. "Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma" International Journal of Molecular Sciences 18, no. 6: 1111. https://doi.org/10.3390/ijms18061111